Syros Pharmaceuticals, a Watertown, MA-based life sciences company that leverages discovers in gene control to innovate the treatment of cancer and other diseases, completed a $30m Series A financing.
The round was led by ARCH Venture Partners and Flagship Ventures, with participation from the WuXi PharmaTech Corporate Venture Fund, and undisclosed private investors.
The company intends to use the capital to accelerate the discovery and development of novel gene control medicines.
Syros Pharmaceuticals was co-founded by ARCH Venture Partners and Flagship’s VentureLabs unit working with three leaders within the field of gene regulation and translational medicine:
– Richard A. Young, Ph.D., Whitehead Institute, Massachusetts Institute of Technology;
– James “Jay” E. Bradner, M.D., Harvard Medical School, Dana Farber Cancer Institute, Broad Institute; and
– Nathanael Gray, Ph.D., Harvard Medical School, Dana Farber Cancer Institute.
The company, which will be Led by CEO Nancy Simonian, M.D. has executed exclusive, worldwide licensing agreements with the Whitehead Institute and the Dana Farber Cancer Institute. Licenses cover Syros’ lead scientific platform components, including Super-Enhancer technologies and methods.
FinSMEs
12/04/2013